PipelineReview.com2d
Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.
PipelineReview.com3d
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and ...
PipelineReview.com3d
Amgen announces robust weight loss with maritide in people living with obesity or overweight at 52 weeks in a phase 2 study
THOUSAND OAKS, CA, USA I November 26, 2024 I Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, ...
PipelineReview.com3d
Brenig Therapeutics Announces the Initiation of First-in-Human Clinical Trial of BT-267, a Best-in-Class LRRK2 Inhibitor for Parkinson’s Disease
DOVER, DE, USA I November 26, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential ...
PipelineReview.com3d
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
NEW HAVEN, CT, USA I November 25, 2024 I Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
PipelineReview.com3d
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer’s Treatment
POTOMAC, MD, USA I November 25, 2024 I IGC Pharma, Inc. (NYSE American: IGC) (“IGC Pharma” or the “Company”) today announced additional interim data from its ongoing Phase 2 clinical trial evaluating ...
PipelineReview.com3d
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment
YONGIN, South Korea I November 25, 2024 I GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with ‘GC1130A’, an innovative ...
PipelineReview.com3d
SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy (SCG101) at the AASLD Liver Meeting 2024
SINGAPORE I November 25, 2024 I SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, ...
PipelineReview.com3d
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of ...